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Expression of TGF- and fibrogenic genes in transplant recipi- mechanism of the nephrotoxicity in renal allograft recipi-
ents with tacrolimus and cyclosporine nephrotoxicity. ents remains elusive. Based on clinical and experimental
Background. Long-term treatment with cyclosporine (CsA) studies, transforming growth factor- (TGF-) seems toor tacrolimus (Tac) results in chronic nephrotoxicity. Trans-
have emerged as a leading candidate responsible for thisforming growth factor- (TGF-) and other pro-fibrogenic
effect. A number of in vitro and in vivo studies, includingmolecules have been known to contribute to this side effect.
A comparison of intrarenal expression of TGF- and other our own, have demonstrated hyperexpression of TGF-
fibrogenic genes in biopsies from patients with either CsA or with Tac and CsA treatment [1–13]. Our experimental
Tac nephrotoxicity have not been documented. This study com- studies also demonstrated TGF- to be a potent immu-pared the expression of TGF-, collagen, fibronectin, metallo-
nosuppressive cytokine with fibrogenic properties as itproteinases (MMP-2, -9), tissue inhibitors of metalloprotein-
induces the production of extracellular matrix proteins,ases (TIMP-2) and osteopontin in renal biopsies obtained from
renal transplant recipients treated with either CsA or Tac as collagen and fibronectin [2]. Therefore, it is conceivable
primary immunosuppressive agents. that CsA and Tac exert their nephrotoxic effects via the
Methods. Using RT-PCR, intrarenal expression of TGF-, induction of TGF- and other pro-fibrogenic molecules.collagen, fibronectin, MMP-2, MMP-9 and TIMP-2 were stud-
This study was conducted to compare the intrarenalied in renal biopsies from patients with histological diagnosis of
expression of TGF- and other fibrogenic genes suchCsA or Tac nephrotoxicity and acute rejection. TGF- protein
expression was studied by staining section of biopsies with anti- as collagen, fibronectin, metalloproteinases (MMP-2, 9),
TGF- antibody. tissue inhibitors of metalloproteinases (TIMP-2), and
Results. Intrarenal expression of TGF-, collagen, fibronec-
osteopontin in renal tissues from renal transplant recipi-tin, MMP-2, TIMP-2, and osteopontin were significantly in-
ents who experienced renal dysfunction when receivingcreased in patients treated with Tac nephrotoxicity compared
with CsA nephrotoxicity. The intrarenal mRNA expression of CsA or Tac as primary immunosuppressive drugs.
these genes was higher in patients diagnosed with Tac/CsA
nephrotoxicity compared to acute rejection.
Conclusions. This study compares the intrarenal expression METHODS
of TGF- and profibrogenic genes in renal transplant recipients Patientstreated with Tac and CsA. The results show that patients diag-
nosed with Tac nephrotoxicity exhibit increased expression of Renal biopsies from 47 transplant recipients who re-
profibrogenic genes compared to CsA nephrotoxicity. ceived either CsA or Tac for maintenance immunosup-
pression were obtained after an informed consent and
an approval from Institutional Review Board. These bi-
Cyclosporine (CsA) and tacrolimus (Tac) are two pri- opsies were performed for elevated plasma creatinine
mary immunosuppressive agents used for the prevention (20% baseline) using an 18-gauge Trucut needle with
of acute rejection. However, nephrotoxicity associated ultrasound guidance. An extra core was obtained and
with these drugs remains a significant problem. The exact snap frozen in liquid nitrogen for this study. From 1997
to 1998, a total of 47 biopsies were performed. A total
of 33 patients were diagnosed with nephrotoxicity: CsAKey words: immunosuppression, transforming growth factor-, acute
toxicity (N  16) and Tac toxicity (N  17). Fourteenrejection, cytokine, collagen, fibronectin, metalloproteinase, TIMP-2,
kidney transplant. patients diagnosed with acute rejection also were in-
cluded in this study. The mean age at the time of biopsyReceived for publication March 19, 2002
for these patients was calculated for the three groups:and in revised form May 30, 2002
Accepted for publication July 11, 2002 CsA toxicity (45  4 years old), Tac toxicity (49  3
years old) and acute rejection (50 4 years old). Among 2002 by the International Society of Nephrology
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the CsA toxicity, Tac toxicity, and acute rejection pa- TGTCGGCGATAAGG-3 [19]; for TIMP-2, coding
5-AAA CGA CAC TTA TGG CAA AC-3 and non-tients there were 10, 7 and 8 males, respectively. Simi-
coding 5-ACA GGA AGC GTC ACT TCT CT-3 [20];larly, there were 11, 12 and 6 Caucasians in these groups,
and for osteopontin, coding 5-CATCACC TGT GCCArespectively. There were no significantly differences for
TACCAG-3 and noncoding 5 GGGGACAACTGGthese parameters in these groups. At the time of biopsy
AGTGA AA-3 [21]. The PCR products were resolvedthe degree of renal function was measured by plasma
in 1% agarose gel electrophoresis. Ethidium bromidecreatinine; for the CsA toxicity, Tac toxicity and acute
stained specific bands were visualized under UV lightrejection groups, the creatinine levels were 2.6  0.5,
and photographed. The densitometric analysis of the2.4  0.2 and 2.5  0.4 mg/dL, respectively (NS). The re-
specific bands was made using Alpha-Imager (Alpha In-nal dysfunction requiring biopsy occurred after a mean
notech Corp., San Leandro, CA, USA) and data areperiod of 22 months (4 to 78 months) for the CsA toxicity
represented as the ratio of the specific gene to -actin.group, 28 months (3 to 84 months) for the Tac toxicity
group, and 14.5 months (4 to 48 months) for the acute
Immunohistochemistry for TGF-1 protein expressionrejection group. The mean CsA dose and trough level
in kidney biopsies
values at the time of biopsy were 325 mg/day and 189
Kidney biopsy tissue was fixed in formalin and paraffinng/mL (158 to 393 ng/mL), respectively. The correspond-
embedded. Hematoxylin, eosin and Mason’s trichromeing values for Tac were 6 mg/day and 7.2 (4 to 14 ng/mL).
staining were used to assess histologic changes. TGF-1One tissue core was immediately snap-frozen in liquid
protein expression was studied using immunohistochem-nitrogen and stored at80C. The pathological diagnosis
istry [2]. Formalin fixed tissues were paraffin embeddedwas confirmed by a nephropathologist. The histological
and sliced into fine sections, deparaffinized in xylenefindings of acute rejection and CsA/Tac nephrotoxicity
and rehydrated in graded ethanol to phosphate-bufferedwere correlated to TGF- and other fibrogenic mole-
saline (PBS). After blocking endogenous peroxidase ac-cules in a blinded fashion. The intrarenal expression of
tivity with methanol/peroxide (18:1 vol/vol) for 30 min-TGF-, collagen, fibronectin, MMPs, TIMP-2, and osteo-
utes, nonspecific binding was blocked for one hour withpontin were compared in patients diagnosed with CsA/
1.5% avidin/biotin diluted in PBS supplemented withTac nephrotoxicity and rejection treated with CsA or Tac.
10% normal horse serum and 3% bovine serum albumin
(BSA). The tissue sections then interacted overnight atDetection of mRNA by RT-PCR in kidney biopsies
4C with 1D11 monoclonal antibody (mAb; 50 mg/mL)To study the intrarenal expression of TGF- and other
in the PBS mentioned earlier. Following ample washings
fibrogenic molecules, total RNA was isolated from a core with PBS, the slides were incubated for one hour with
of biopsy from transplant patients using the SV Total 1:1000 diluted biotin labeled anti-mouse IgG horse anti-
RNA isolation System (Promega, Madison, WI, USA) serum at room temperature, again washed extensively
and the quality of RNA was verified by 260/280 nm ratio. in PBS, and then in the ABC solution for 30 minutes.
One microgram of RNA was reverse transcribed to cDNA The slides were then developed for 10 minutes in diami-
using Superscript First Strand Synthesis system for re- nobenzidine (DAB) and rinsed with water for 10 min-
verse transcription-polymerase chain reaction (RT-PCR; utes. The slides were then counterstained with hematox-
Life Technologies, Rockville, MD, USA). The amplifica- ylin followed by dehydration in graded ethanol and
tion by PCR was carried out using 1 L of cDNA, 2 L xylene. The slides were mounted with Permount for eval-
each of 2.5 mmol/L coding and non-coding oligonucleo- uation. Samples from each group were graded for histo-
tide primers, and Platinum PCR Supermix (Life Technolo- pathological changes and immunohistochemistry stain-
gies). The primer sequences for TGF-1 were: coding ing. The intensity of immunostaining was graded from
5-GAA GCG GAA GCG CAT CGA GG-3, noncod- 0 (no staining) to 4	 (maximum staining).
ing 5-TCC ACG GCT CAA CCA CTG CC-3 [14]; for
Data analysis-actin, coding 5-TGA CGG GGT CAC CCA CAC
TGT GAA CAT CTA-3, noncoding 5-CTT GAA GCA The expression of TGF- and other fibrogenic mole-
TTT GCG GTG GAC GAT GGA GGG-3 [15]; for cules were correlated with histologically confirmed acute
collagen 
1, coding 5-TCT TTC CTC ATG CAC ACT rejection and CsA/Tac toxicity. The mRNA expression
GC-3 and noncoding 5-TTC AGC GTT TCA GAC of TGF- and other fibrogenic molecules also were com-
ACA GG-3 [16]; and for fibronectin, coding 5-TCC pared between patients with CsA and Tac nephrotoxic-
ACA AGC GTC ATG AAG AG-3 and noncoding ity. Statistical analyses were performed using InStat, a
5-ATA CCA CAC CAG GCT TCA GG-3[17]; for Windows-based statistical program from GraphPad Soft-
MMP-2, coding 5-GTG CTG AAG GAC ACA CTA ware (San Diego, CA, USA). The data are expressed as
AA-3 and noncoding 5-TTG CCA TCC TTC TTT mean  SEM. Significance was assessed by the Student
TCA AA-3 [18]; for MMP-9, coding 5-CACTGT unpaired t test and a value of P  0.05 was considered
to be significant.CCACCCCTCAGAGC-3and noncoding 5GCCACT
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Fig. 1. Transforming growth factor- (TGF-) mRNA expression. The Fig. 2. Fibronectin mRNA expression. The results of fibronectin mRNA
results of TGF- mRNA are expressed as ratio of TGF- with the are expressed as ratio of fibronectin with the housekeeping gene -actin.
housekeeping gene -actin. Open bars represent patients with CsA Open bars represent patients with CsA nephrotoxicity, hatched bar
nephrotoxicity, hatched bar Tac nephrotoxicity and crosshatched bar Tac nephrotoxicity and crosshatched bar acute rejection. An increased
acute rejection. An increased expression with Tac nephrotoxicity com- expression with Tac nephrotoxicity compared to CsA nephrotoxicity
pared to CsA nephrotoxicity (P 0.05) and acute rejection (P 0.0001) (P  0.01) and acute rejection (P  0.03) is shown. No difference
is shown. between patients with CsA nephrotoxicity and acute rejection also is
shown.
RESULTS
A total of 47 biopsies were performed in 47 transplant
recipients. Of these 23 were on CsA as an immunosup-
pressive agent and the remaining 24 were on Tac. Acute
rejection and CsA/Tac nephrotoxicity was diagnosed in
14 and 33 patients and recipients, respectively. CsA and
Tac nephrotoxicity was diagnosed in 16 and 17 recipients,
respectively.
Renal function
The levels of creatinine of patients diagnosed with Tac
or CsA nephrotoxicity were not statistically different
(2.4  0.3 vs. 2.1  0.2 mg/dL, P  0.4).
TGF- mRNA expression
The results of TGF- expression are shown in Figure 1. Fig. 3. Collagen mRNA expression. The results of collagen mRNA are
expressed as the ratio of collagen with the housekeeping gene -actin.Patients with CsA and Tac nephrotoxicity exhibited sig-
Open bars represent patients with CsA nephrotoxicity, hatched bar Tacnificantly increased expression of TGF- compared to nephrotoxicity and crosshatched acute rejection. A 300% increased
those diagnosed with acute rejection (0.4  0.03, 0.2  expression with Tac nephrotoxicity compared to CsA nephrotoxicity
and acute rejection (P  0.03) is shown. No difference among patients0.09 vs. 0.007 0.003, P 0.001 and0.05, respectively).
with CsA nephrotoxicity and acute rejection also is shown.The expression of TGF- mRNA was higher in patients
with Tac nephrotoxicity compared to CsA nephrotoxic-
ity (N  17, 0.4  0.03 vs. N  16, 0.2  0.09, P  0.05).
rotoxicity compared those with acute rejection (0.4 
Fibronectin mRNA expression 0.1 vs. 0.1  0.07). However, the expression in patients
The results of fibronectin mRNA expression are with CsA nephrotoxicity was identical to patients with
shown in Figure 2. The expression of fibronectin mRNA acute rejection (0.1  0.04 vs. 0.1  0.04).
was significantly (P  0.01) increased in patients with
Collagen mRNA expressionTac nephrotoxicity than with CsA nephrotoxicity (0.4 
0.1 vs. 0.1  0.04, P  0.0001). Similar to TGF- expres- The results of collagen mRNA expression are shown in
sion, the expression of fibronectin mRNA was signifi- Figure 3. The expression of collagen mRNA was not sig-
nificantly different between patients with acute rejectioncantly (P 0.03) higher in patients treated with Tac neph-
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Fig. 5. Osteopontin (OPN) mRNA expression. The results of OPN
mRNA are expressed as the ratio of osteopontin with the housekeeping
Fig. 4. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of gene -actin. Open bars represent patients with CsA nephrotoxicity,
metalloproteinases-2 (TIMP-2) mRNA expression. The results of hatched bar Tac nephrotoxicity and crosshatched bar acute rejection.
MMP-9 and TIMP-2 mRNA are expressed as the ratio of MMP-9 and An increased expression of OPN mRNA with Tac nephrotoxicity com-
TIMP-2 with the housekeeping gene -actin. Symbols are: () patients pared to acute rejection (P  0.05) and CsA nephrotoxicity (P  0.02)
with CsA nephrotoxicity; ( ) Tac nephrotoxicity; () acute rejection. is shown. No difference among patients with acute rejection and CsA-
The decreased MMP-9 mRNA expression in patients with Tac nephro- nephrotoxicity is also seen.
toxicity compared to patients with CsA nephrotoxicity is shown (P 
0.05). No difference in the expression of TIMP-2 mRNA between pa-
tients with CsA and Tac nephrotoxicity can be seen. However, higher
levels than patients with acute rejection can be appreciated.
pression of OPN mRNA was significantly increased com-
pared to acute rejection (2.1  0.15 vs. 1.6  0.2, P 
0.05) and CsA nephrotoxicity (2.1  0.15 vs. 1.5  0.02,
P  0.02; Fig. 5). No difference was observed amongand CsA nephrotoxicity (0.1 0.08 vs. 0.16 0.5). How-
patients with acute rejection and CsA nephrotoxicity.ever, the mRNA expression increased threefold in pa-
tients with Tac compared to CsA nephrotoxicity (0.3 
Intrarenal expression of TGF- protein0.16 vs. 0.1  0.08, P  0.2).
The intrarenal expression of TGF- protein by was
TIMP-2 and MMP-9 mRNA expression examined using an immuno-reaction with anti-TGF-
antibody. The results of TGF- protein expression inThe results of intrarenal expression of metalloprotein-
biopsies from patients with CsA or Tac nephrotoxicityase MMP-9 mRNA are shown in Figure 4. The expres-
are shown from a representative slide of immunohisto-sion of MMP-9 was increased in patients with Tac/CsA
chemical staining for TGF- in renal tissues. A and Cnephrotoxicity compared to acute rejection (0.05 0.01).
are sections stained with control antibody and B andThe mRNA expression of MMP-9 in CsA treated pa-
D were stained with anti-TGF- antibody (Fig. 6). Antients was significantly higher than with Tac (0.6  0.09
intense staining of TGF- (Fig. 6D) can be seen in Tacvs. 0.9  0.09, P  0.05). The results of tissue inhibitor
nephrotoxicity compared to CsA nephrotoxicity. Stain-of metalloproteinase-2 (TIMP-2) mRNA expression are
ing of TGF- protein was not performed in tissue sec-demonstrated also in Figure 4. The expression of TIMP-2
tions from patients with acute rejectionmRNA was not different between patients with Tac and
CsA nephrotoxicity (0.9  0.25 vs. 0.9  0.26); however,
levels were higher than patients with acute rejection DISCUSSION
(0.1  0.01). We also calculated the ratio of MMP-9/ Long-term treatment with CsA is associated with neph-
TIMP-2 and it was lower in patients diagnosed with CsA rotoxicity [22]. Initially it was believed that Tac treatment
nephrotoxicity than Tac nephrotoxicity. would result in decreased nephrotoxicity. However, stud-
ies of Randhawa et al [23] and Laskow et al [24] noted
Osteopontin mRNA expression that the major toxicities associated with tacrolimus were
Osteopontin (OPN) is a TGF- inducible glycopro- nephrotoxicity, neurotoxicity and diabetes. Shapiro et al
tein, the synthesis of which in the distal tubules is in- also studied the efficacy and safety of tacrolimus- and
creased in connection with tubulointerstitial nephritis. cyclosporine-based immunosuppressive regimens in kid-
The results from our study demonstrate that in patients ney transplant recipients and observed that the side ef-
fects of tacrolimus included nephrotoxicity, neurotoxicity,with nephrotoxicity and those treated with Tac, the ex-
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Fig. 6. Intrarenal expression of TGF- protein. Representative slides of immunohistochemical staining for TGF- in renal tissues from patients
with CsA and Tac nephrotoxicity are shown. A and C are sections stained with control antibody and B and D were stained with anti-TGF-
antibody. An intense staining of TGF- can be seen in Tac nephrotoxicity compared to CsA nephrotoxicity.
and diabetogenicity, and they were comparable to those strate that tacrolimus treatment significantly increased
the intrarenal expression of TGF- compared to the pa-seen with CsA [25]. Platz et al also compared the effects
of Tac and CsA in renal transplant patients and showed tients treated with CsA (P  0.05). In addition, the ex-
pression of TGF- mRNA was significantly (P  0.05)that the late renal insufficiency appeared in 23.3% of
CsA and in 29.4% of Tac treated patients [26]. A number higher in patients diagnosed with drug nephrotoxicity
than with acute rejection. Similarly, significantly moreof other studies revealed similar degree of nephrotoxicity
in Tac treated patients [27–30]. Besides these clinical intense staining for TGF- protein was observed in biop-
sies from patients with Tac nephrotoxicity compared tofindings, similar results have been documented in several
animal models [31–32] including those of Shihab et al CsA nephrotoxicity (Fig. 6).
To further understand the events associated with an[8], who also showed the induction of TGF- following
treatment with Tac in salt depleted rats. From our study increased expression of TGF- and those leading to neph-
rotoxicity in renal transplant recipients, we also studiedin combination with these clinical and experimental stud-
ies, it is apparent that—like CsA—Tac induces hyperex- the intrarenal expression of collagen and fibronectin in
these patients. Our study demonstrates that in patientspression of TGF- and other fibrogenic molecules in
renal transplant patients. diagnosed with Tac nephrotoxicity, mRNA expression
of fibronectin was significantly increased compared toThere is a paucity of data demonstrating the differ-
ences in CsA and Tac induced nephrotoxicity and their acute rejection (P  0.01) and CsA nephrotoxicity (P 
0.03). Similarly, the expression of collagen was increasedmechanism in renal transplant recipients. To the best of
our knowledge, a comparison of intrarenal expression of 300% in the patients with tacrolimus nephrotoxicity com-
pared to patients diagnosed with CsA nephrotoxicityfibrogenic genes in transplant patients treated with either
CsA or Tac has not been explored. Our results demon- and those receiving CsA. These results demonstrate that
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besides up-regulation of TGF- expression, these drugs in acute rejection; its role in various forms of renal in-
jury has been highlighted [39]. Our study demonstratescause the increased expression of extracellular matrix
proteins, thus facilitating the process of drug-associated that the expression of OPN mRNA was significantly
increased with Tac nephrotoxicity compared to acuterenal damage.
During tissue damage, a balance in the synthesis and rejection (P  0.05) and CsA nephrotoxicity (P  0.03).
To the best of our knowledge, mRNA expression ofdegradation of extracellular matrix proteins has to be
maintained. Metalloproteinases, also termed gelatinases, OPN has not been explored in detail, nor has it been
compared in patients with Tac or CsA nephrotoxicity.have been described as extracellular matrix degrading
enzymes and are known to play a key role to maintaining In summary, this report highlights the expression of
TGF- and pro-fibrogenic molecules in the renal tissuesthis balance [33]. There are number of metallopro-
teinases numbered from MMP-1 to -17 with a variety of of renal transplant recipients treated with either Tac or
CsA. The results demonstrate, to our knowledge for thefunctional roles. Changes in the expression of metallo-
proteinases translate into altered extracellular matrix first time, that the expression of these molecules in-
creases considerably in recipients with Tac nephrotoxic-protein turnover and may play a role in histopathological
changes [34]. Increased levels of metalloproteinases are ity when compared with CsA nephrotoxicity and with
acute rejection irrespective of the drug treatment. Ouroften associated with disease status and infiltration of
inflammatory cells [35]. A selective increase in these studies may explain in part the mechanism of nephrotox-
icity observed in renal transplant recipients treated withproteins may play a role in the ultimate fibrosis and other
histological changes irrespective of the insulting injury. Tac and CsA. We studied only the TGF- protein expres-
sion in these biopsies; however, studies on the expressionThe expression of MMP-9 was statistically increased
in patients with CsA nephrotoxicity compared to pa- of other proteins and circulating levels of the protein
relevant to fibrogenesis will further delineate the role oftients with Tac nephrotoxicity. However, the difference
among nephrotoxicity patients was statistically signifi- these molecules in nephrotoxicity. Also, future studies
with specific inhibitors of TGF- and/or metalloprotein-cant compared to patients with acute rejection. It can
be interpreted that the increased expression of MMP-9 ases will be an avenue to alleviate the side effects of
these agents.continues into the chronic phase of renal damage and
may contribute to the extensive structural remodeling
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